Lv Chaoxiang, He Jiayue, Zhang Qiqi, Wang Tiecheng
The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou 646000, China.
Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Vaccines (Basel). 2025 Jun 4;13(6):608. doi: 10.3390/vaccines13060608.
Nipah virus (NiV) is a highly pathogenic paramyxovirus characterized by zoonotic infection, high mortality, and a lack of effective treatment, posing a serious threat to global public health security. Currently, it still lacks specific treatments or approved vaccines, and is listed as a potential pandemic threat pathogen by the World Health Organization. This paper systematically reviews the core progress and challenges of NiV investigation, with a focus on the development of animal models, vaccine development strategies, treatment strategy, and bottlenecks in translational medicine. Additionally, we discuss the strengths and limitations of existing animal models, including ferrets, hamsters, mice, and non-human primates (NHPs), and assess advances in vaccine platforms such as viral vectors, subunit vaccines, and mRNA-based vaccine candidates. The paper critically reviews the challenges facing translational research, conservation correlates, and outbreak preparedness, while also providing future research directions for pandemic preparedness and public health security strategies.
尼帕病毒(NiV)是一种高致病性副粘病毒,其特点是具有人畜共患感染性、高死亡率且缺乏有效治疗方法,对全球公共卫生安全构成严重威胁。目前,它仍然缺乏特效治疗方法或获批的疫苗,被世界卫生组织列为潜在的大流行威胁病原体。本文系统回顾了尼帕病毒研究的核心进展与挑战,重点关注动物模型的开发、疫苗开发策略、治疗策略以及转化医学中的瓶颈。此外,我们讨论了现有动物模型(包括雪貂、仓鼠、小鼠和非人灵长类动物)的优缺点,并评估了病毒载体、亚单位疫苗和基于信使核糖核酸的候选疫苗等疫苗平台的进展。本文批判性地审视了转化研究面临的挑战、保护性关联因素和疫情防范措施,同时还为大流行防范和公共卫生安全策略提供了未来的研究方向。